Barclays’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $248K | Sell |
1,991
-23,145
| -92% | -$2.41M | ﹤0.01% | 3569 |
|
|
2025
Q4 | $2.63M | Buy |
25,136
+15,360
| +157% | +$1.31M | ﹤0.01% | 2729 |
|
|
2025
Q3 | $613K | Sell |
9,776
-2,403
| -20% | -$107K | ﹤0.01% | 3682 |
|
|
2025
Q2 | $275K | Buy |
12,179
+12,116
| +19,232% | +$284K | ﹤0.01% | 4090 |
|
|
2025
Q1 | $1.76K | Hold |
63
| – | – | ﹤0.01% | 5003 |
|
|
2024
Q4 | $756 | Hold |
63
| – | – | ﹤0.01% | 5149 |
|
|
2024
Q3 | $1.04K | Hold |
63
| – | – | ﹤0.01% | 5123 |
|
|
2024
Q2 | $618 | Hold |
63
| – | – | ﹤0.01% | 4703 |
|
|
2024
Q1 | $917 | Hold |
63
| – | – | ﹤0.01% | 4950 |
|
|
2023
Q4 | $911 | Hold |
63
| – | – | ﹤0.01% | 5116 |
|
|
2023
Q3 | $1.49K | Sell |
63
-10
| -14% | -$215 | ﹤0.01% | 4471 |
|
|
2023
Q2 | $968 | Sell |
73
-404
| -85% | -$24.5K | ﹤0.01% | 4367 |
|
|
2023
Q1 | $37.3K | Buy |
477
+11
| +2% | +$1.27K | ﹤0.01% | 4513 |
|
|
2022
Q4 | $38.7K | Hold |
466
| – | – | ﹤0.01% | 4636 |
|
|
2022
Q3 | $43K | Hold |
466
| – | – | ﹤0.01% | 3828 |
|
|
2022
Q2 | $70K | Sell |
466
-508
| -52% | -$92.7K | ﹤0.01% | 3917 |
|
|
2022
Q1 | $237K | Hold |
974
| – | – | ﹤0.01% | 3321 |
|
|
2021
Q4 | $294K | Buy |
974
+470
| +93% | +$151K | ﹤0.01% | 3430 |
|
|
2021
Q3 | $209K | Buy |
504
+423
| +522% | +$147K | ﹤0.01% | 3602 |
|
|
2021
Q2 | $24K | Sell |
81
-474
| -85% | -$104K | ﹤0.01% | 4443 |
|
|
2021
Q1 | $114K | Buy |
555
+47
| +9% | +$10.3K | ﹤0.01% | 3947 |
|
|
2020
Q4 | $102K | Sell |
508
-73
| -13% | -$15.2K | ﹤0.01% | 4129 |
|
|
2020
Q3 | $97K | Sell |
581
-56
| -9% | -$12.8K | ﹤0.01% | 4273 |
|
|
2020
Q2 | $158K | Buy |
637
+149
| +31% | +$34.8K | ﹤0.01% | 4238 |
|
|
2020
Q1 | $89K | Sell |
488
-112
| -19% | -$28.2K | ﹤0.01% | 4883 |
|
|
2019
Q4 | $173K | Sell |
600
-21
| -3% | -$5.82K | ﹤0.01% | 5142 |
|
|
2019
Q3 | $170K | Sell |
621
-41
| -6% | -$15.9K | ﹤0.01% | 5094 |
|
|
2019
Q2 | $249K | Buy |
662
+474
| +252% | +$141K | ﹤0.01% | 4916 |
|
|
2019
Q1 | $50K | Buy |
188
+119
| +172% | +$28.3K | ﹤0.01% | 5878 |
|
|
2018
Q4 | $15K | Sell |
69
-174
| -72% | -$54K | ﹤0.01% | 6035 |
|
|
2018
Q3 | $109K | Buy |
243
+195
| +406% | +$84.7K | ﹤0.01% | 5471 |
|
|
2018
Q2 | $20K | Sell |
48
-325
| -87% | -$155K | ﹤0.01% | 6200 |
|
|
2018
Q1 | $204K | Buy |
373
+282
| +310% | +$175K | ﹤0.01% | 4816 |
|
|
2017
Q4 | $55K | Sell |
91
-352
| -79% | -$164K | ﹤0.01% | 5698 |
|
|
2017
Q3 | $205K | Buy |
+443
| New | +$189K | ﹤0.01% | 4406 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6986 |
|
Other funds holding PVLA
SCM
FLAM
BI
FLSM
VCM
Barclays's PVLA Position: Q1 2026 in Review
Barclays reduced its Palvella Therapeutics (PVLA) stake by 92% in Q1 2026, selling an estimated $2.41M and leaving 1,991 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #3569.
Barclays first reported a position in PVLA in Q3 2017 and has held it in 35 quarters since. The position peaked at $2.63M in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.
- Barclays held 1,991 shares of Palvella Therapeutics worth $248K as of Q1 2026.
- Barclays sold 23,145 Palvella Therapeutics shares in Q1 2026, an estimated $2.41M.
- Palvella Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3569 holding.
- Barclays first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 35 quarters since.
- Barclays's Palvella Therapeutics position peaked at $2.63M in Q4 2025.
- 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.